Details for New Drug Application (NDA): 211449

NDA 211449 describes CLOBAZAM, which is a drug marketed by Accord Hlthcare, Alkem Labs Ltd, Amneal, Aurobindo Pharma Ltd, Bionpharma, Chartwell Molecular, Hetero Labs Ltd Iii, Hikma, Lupin Ltd, Norvium Bioscience, Taro, Teva Pharms Usa, Upsher Smith Labs, Vistapharm, Amneal Pharms Co, Apotex, Breckenridge, Celltrion, Micro Labs, MSN, Piramal Hlthcare Uk, and Zydus Pharms, and is included in thirty-one NDAs. It is available from twenty-one suppliers. Additional details are available on the CLOBAZAM profile page.

The generic ingredient in CLOBAZAM is clobazam. There are ten drug master file entries for this compound. Twenty-three suppliers are listed for this compound. Additional details are available on the clobazam profile page.

Summary for 211449

Tradename:	CLOBAZAM
Applicant:	Zydus Pharms
Ingredient:	clobazam
Patents:	0

Pharmacology for NDA: 211449

Mechanism of Action

Cytochrome P450 2D6 Inhibitors Cytochrome P450 3A4 Inducers

Suppliers and Packaging for NDA: 211449

Tradename	Generic Name	Dosage	NDA	Application Type	Supplier	National Drug Code	Package Code	Package
CLOBAZAM	clobazam	TABLET;ORAL	211449	ANDA	Zydus Pharmaceuticals USA Inc.	70710-1325	70710-1325-1	100 TABLET in 1 BOTTLE (70710-1325-1)
CLOBAZAM	clobazam	TABLET;ORAL	211449	ANDA	Zydus Pharmaceuticals USA Inc.	70710-1326	70710-1326-1	100 TABLET in 1 BOTTLE (70710-1326-1)

Profile for product number 001

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET;ORAL			Strength	10MG
Approval Date:	Oct 22, 2018	TE:	AB	RLD:	No

Profile for product number 002

Active Rx/OTC/Discontinued:	RX	Dosage:	TABLET;ORAL			Strength	20MG
Approval Date:	Oct 22, 2018	TE:	AB	RLD:	No

Complete Access Available with Subscription